Lomitapide: A novel drug for homozygous familial hypercholesterolemia

Clinical Lipidology

Volumn 9, Issue 1, 2014, Pages 19-32

  Panno, Maria D ^a   Cefalù, Angelo B ^a   Averna, Maurizio R ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

HeFH; HoFH; lipoprotein apheresis; lomitapide; trials

Indexed keywords

EID: 84893829984     PISSN: 17584299     EISSN: 17584302     Source Type: Journal    
DOI: 10.2217/clp.13.74     Document Type: Article

References (61)

1. Lomitapide. Am. J. Cardiovasc. Drugs 11(5), 347-352 (2011).
2. Innerarity TL, Weisgraber KH, Arnold KS et al. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc. Natl Acad. Sci. 84(19), 6919-6923 (1987). (Pubitemid 18025501)
3. Abifadel M, Varret M, Rabes JP et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34(2), 154-156 (2003).
4. Goldstein JL, Hobbs HH, Brown MS et al. Familial Hypercholesterolemia. In: The Methabolic and Molecular Bases of Inherited Disease (8th Edition). Scriver CR (Ed.). Mc Graw-Hill, NY, USA, 2863-2913 (2001).
5. Pisciotta L, Priore Oliva C, Pes GM et al. Autosomal recessive hypercholesterolemia (ARH) and homozygous familial hypercholesterolemia (FH): a phenotypic comparison. Atherosclerosis 188(2), 398-405 (2006). (Pubitemid 44301145)
6. Seftel HC, Baker SG, Sandler MP et al. A host of hypercholesterolaemic homozygotes in South Africa. Br. Med. J. 281(6241), 633-636 (1980). (Pubitemid 10051766)
7. Moorjani S, Roy M, Gagne C et al. Homozygous familial hypercholesterolemia among French Canadians in Quebec Province. Arteriosclerosis 9(2), 211-216 (1989). (Pubitemid 19092104)
8. Fahed AC, Safa RM, Haddad FF et al. Homozygous familial hypercholesterolemia in Lebanon: a genotype/phenotype correlation. Mol. Genet. Metab. 102(2), 181-188 (2011).
9. Mabuchi H, Nohara A, Noguchi T et al. Molecular genetic epidemiology of homozygous familial hypercholesterolemia in the Hokuriku district of Japan. Atherosclerosis 214(2), 404-407 (2011).
10. Benn M, Watts GF, Tybjaerg-Hansen A et al. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J. Clin. Endocrinol. Metab. 97(11), 3956-3964 (2012).
11. Nordestgaard BG, Chapman MJ, Humphries SE et al.; for the European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur. Heart J. 34(45), 3478a-3490a (2013).
12. Ejarque I, Civer M, Francisco Ascaso J et al. Identification and characterization of the first Spanish familial ligand-defective apolipoprotein B homozygote Med. Clin. (Barc.) 116(4), 138-141 (2001). (Pubitemid 33640856)
13. Pisciotta L, Priore Oliva C, Cefalu AB et al. Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia. Atherosclerosis 186(2), 433-440 (2006).
14. Sanchez AP, Cunard R, Ward DM. The selective therapeutic apheresis procedures. J. Clin. Apher. 28(1), 20-29 (2013).
15. Thompson GR, Miller JP, Breslow JL. Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange. Br. Med. J. (Clin. Res. Ed.) 291(6510), 1671-1673 (1985). (Pubitemid 16211891)
16. Robinson JG. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J. Manag. Care Pharm. 19(2), 139-149 (2013).
17. Ito MK, McGowan MP, Moriarty PM. Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J. Clin. Lipidol. 5(Suppl. 3), S38-S45 (2011).
18. Winters JL. Lipid apheresis, indications, and principles. J. Clin. Apher. 26(5), 269-275 (2011).
19. Bambauer R, Bambauer C, Lehmann B et al. LDL-apheresis: technical and clinical aspects. ScientificWorldJournal 2012, 314283 (2012).
20. Thompson GR; HEART-UK LDL Apheresis Working Group. Recommendations for the use of LDL apheresis. Atherosclerosis 198(2), 247-255 (2008).
21. Thompson GR. LDL apheresis. Atherosclerosis 167(1), 1-13 (2003). (Pubitemid 36258395)
22. Hodgins LC, Gordon BR, Parker TS et al. LDL apheresis: an effective and safe treatment for refractory hypercholesterolemia. Cardiovasc. Drug Rev. 20(4), 271-280 (2002). (Pubitemid 36105781)
23. Thompson GR, Catapano A, Saheb S et al. Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. Curr. Opin. Lipidol. 21(6), 492-498 (2010).
24. Græsdal A, Bogsrud MP, Holven KB et al. Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia. J. Clin. Lipidol 6(4), 331-339 (2012).
25. Marais AD, Blom DJ, Firth JC. Statins in homozygous familial hypercholesterolemia. Curr. Atheroscler. Rep. 4(1), 19-25 (2002).
26. Raal FJ, Pilcher GJ, Illingworth DR et al. Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia. Atherosclerosis 135(2), 249-256 (1997). (Pubitemid 28015192)
27. Marais AD, Raal FJ, Stein EA et al. A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis 197(1), 400-406 (2008). (Pubitemid 351284477)
28. Raal FJ, Pilcher GJ, Panz VR et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid lowering therapy. Circulation 124(20), 2202-2207 (2011).
29. Kastelein JJ, Wedel MK, Baker BF et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 114(16), 1729-1735 (2006). (Pubitemid 44607121)
30. Akdim F, Visser ME, Tribble DL et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am. J. Cardiol. 105(10), 1413-1419 (2010).
31. Visser ME, Wagener G, Baker BF et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur. Heart J. 33(9), 1142-1149 (2012).
32. Raal FJ, Santos RD, Blom DJ et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375(9719), 998-1006 (2010).
33. Seidah NG, Benjannet S, Wickham L et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc. Natl Acad. Sci. USA 100(3), 928-933 (2003). (Pubitemid 36183932)
34. Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK. The PCSK9 decade. J. Lipid Res. 53(12), 2515-2524 (2012).
35. Stein EA, Mellis S, Yancopoulos GD et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N. Engl J. Med. 366(12), 1108-1118 (2012).
36. Stein EA, Gipe D, Bergeron J et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a Phase 2 randomised controlled trial. Lancet 380(9836), 29-36 (2012).
37. McKenney JM, Koren MJ, Kereiakes DJ et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J. Am. Coll. Cardiol. 59(25), 2344-2353 (2012).
38. Roth EM, McKenney JM, Hanotin C et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N. Engl. J. Med. 367(20), 1891-1900 (2012).
39. Dias CS, Shaywitz AJ, Wasserman SM et al. Effects of AMG 145 on low density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose Phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J. Am. Coll. Cardiol. 60(19), 1888-1898 (2012).
40. Koren MJ, Scott R, Kim JB et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, Phase 2 study. Lancet 380(9858), 1995-2006 (2012).
41. Raal F, Scott R, Somaratne R et al. Low-density lipoprotein cholesterol lowering effects of AMG145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 126(20), 2408-2417 (2012).
42. Giugliano RP, Desai NR, Kohli P et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, Phase 2 study. Lancet 380(9858), 2007-2017 (2012).
43. Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal F. Trial evaluating AMG145, a PCSK9 antibody, in patients with homozygous FH: results of an initial dose scheduling study. Presented at: Abstract Book of the 81th European Atherosclerosis Society Congress. Lyon, France, 2-5 June, 2013 (Abstract: 1625).
44. Guerin M. Reverse cholesterol transport in familial hypercholesterolemia. Curr. Opin. Lipidol. 23(4), 377-385 (2012).
45. Cannon CP, Shah S, Dansky HM et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N. Engl. J. Med. 363(25), 2406-2415 (2010).
46. Raabe M, Véniant MM, Sullivan MA et al. Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice. J. Clin. Invest. 103(9), 1287-1298 (1999). (Pubitemid 29218299)
47. Kane JP, Havel RJ, Scriver CR, Beaudet AL. The Metabolic Basis of Inherited Disease (6th Edition). Scriver CR (Ed.), McGraw-Hill, NY, USA (1989).
48. Wetterau JR, Lin MC, Jamil H. Microsomal triglyceride transfer protein. Biochim. Biophys. Acta 1435(2), 136-150 (1997). (Pubitemid 27138415)
49. Hussain MM, Rava P, Walsh M et al. Multiple functions of microsomal triglyceride transfer protein. Nutr. Metab. (Lond.). 9, 14 (2012).
50. Haghpassand M, Wilder D, Moberly JB. Inhibition of apolipoprotein B and triglyceride secretion in human hepatoma cells (HepG2). J. Lipid Res. 37(7), 1468-1480 (1996) (Pubitemid 26249978)
51. Golberg CA. Emerging low-density lipoprotein therapies: microsomal triglyceride transfer protein inhibitors. J. Clin. Lipidol. 7(Suppl. 3), S16-S20 (2013).
52. Gordon DA, Jamil H. Progress towards understanding the role of microsomal triglyceride transfer protein in apolipoprotein-B lipoprotein assembly. Biochim. Biophys. Acta 1486(1), 72-83 (2000). (Pubitemid 30336793)
53. Sulsky R, Robl JA, Biller SA et al. Carboxamido-1,3,2- dioxaphosphorinanes, potent inhibitors of MTP. Bioorg. Med. Chem. Lett. 14(20), 5067-5070 (2004). (Pubitemid 39233367)
54. Robl JA, Sulsky R, Sun CQ et al. A novel series of highly potent benzimidazole-based microsomal triglyceride transfer protein inhibitors. J. Med. Chem. 44(6), 851-856 (2001). (Pubitemid 32861609)
55. Samaha FF, McKenney J, Bloedon LT et al. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat. Clin. Pract. Cardiovasc. Med. 5(8), 497-505 (2008).
56. Wetterau JR, Gregg RE, Harrity TW et al. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science 282 (5389), 751-754 (1998). (Pubitemid 28489389)
57. Shiomi M, Ito T. MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion. Eur. J. Pharmacol. 431(1), 127-131 (2001). (Pubitemid 33082160)
58. Liao W, Hui TY, Young SG et al. Blocking microsomal triglyceride transfer protein interferes with ApoB secretion without causing retention or stress in the ER. J. Lipid Res. 44(5), 978-985 (2003). (Pubitemid 37279657)
59. Cuchel M, Bloedon LT, Szapary PO et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N. Engl. J. Med. 356(2), 148-156 (2007). (Pubitemid 46089675)
60. Cuchel M, Meagher EA, du Toit Theron H et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, Phase 3 study. Lancet 381(9860), 40-46 (2013).
61. Cuchel M, Meagher EA, du Toit Theron H et al. Apheresis treatment does not affect the lipid-lowering efficacy of lomitapide, a microsomal triglyceride transfer protein inhibitor, in patients with homozygous familial hypercholesterolemia. Circulation 126, Abstract 17396 (2012).